Tofacitinib Market Report 2025

The tofacitinib market size has grown rapidly in recent years. It will grow from $3.08 billion in 2024 to $3.44 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to clinical efficacy and trials, regulatory approvals, rise in incidence of targeted conditions, physician prescribing patterns, patient acceptance.

The tofacitinib market size is expected to see rapid growth in the next few years. It will grow to $5.75 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to expanded indications, market access initiatives, competitive landscape, real-world evidence, patient-centric healthcare. Major trends in the forecast period include focus on pediatric rheumatoid arthritis treatment, exploration of tofacitinib in dermatological conditions, strategic collaborations and partnerships, integration of real-world evidence in treatment guidelines, focus on personalized medicine approaches.

The expected rise in the prevalence of rheumatoid arthritis is anticipated to fuel the growth of the tofacitinib market. Rheumatoid arthritis, an autoimmune and inflammatory disorder affecting joints, internal organs, hands, and feet, sees tofacitinib medications targeting Janus kinase enzymes, preventing their activity and mitigating inflammation. For example, data from the National Arthritis Data Workgroup in February 2022 revealed that over 52.5 million adults in the United States, exceeding 22% of the population, had received diagnoses of arthritis or other rheumatic diseases. Predictions indicate that adults aged 18 and above with arthritis could reach 67 million by 2030. Thus, the increasing prevalence of rheumatoid arthritis contributes to the growth of the tofacitinib market.

The growing number of patients grappling with inflammatory bowel disease is poised to propel the tofacitinib market's expansion. Inflammatory Bowel Disease (IBD), encompassing chronic inflammatory conditions such as Crohn's disease and ulcerative colitis, witnesses tofacitinib's pivotal role in managing symptoms by inhibiting Janus kinase (JAK) enzymes and promoting mucosal healing. Statistics from Crohn's and Colitis Canada in June 2023 estimated that over 322,600 Canadians were living with IBD, accounting for about 0.82% of the population. Projections suggest that by 2035, around 470,000 Canadians, or approximately 1.1% of the population, may be living with IBD. This ongoing prevalence of IBD contributes to the escalating growth of the tofacitinib market.

Major companies in the tofacitinib market are developing innovative ointments, such as tofacitinib ointment, to improve targeted delivery and enhance treatment outcomes for patients with inflammatory skin conditions. Tofacitinib ointment is a topical JAK inhibitor that effectively treats mild to moderate atopic dermatitis, providing a steroid-free option for patients with unmet treatment needs. For instance, in June 2023, Intas Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Tofatas, a DCGI-approved tofacitinib ointment (2% w/w) for treating mild to moderate atopic dermatitis (AD) in adults. This launch marks the introduction of the first approved topical JAK inhibitor in India after a 15-year gap in innovative therapies for this condition. By offering a steroid-free alternative, Tofatas addresses a critical treatment gap, potentially improving patients' quality of life and expanding tofacitinib's therapeutic applications in dermatology.

Major companies in the tofacitinib market are placing increased emphasis on introducing topical tofacitinib medications to gain a competitive advantage. Topical tofacitinib refers to a formulation designed for topical application on the skin. A noteworthy instance is Intas Pharmaceuticals, an India-based pharmaceutical company, which launched Tofacitinib Topical (JAKi) in June 2023 for treating mild to moderate atopic dermatitis (AD) in India. This marks the first approval of a JAK inhibitor for AD in India. The successful Phase III clinical study of TOFATAS (Tofacitinib Ointment 2% w/w) demonstrated notable safety and efficacy in atopic dermatitis patients. The introduction of TOFATAS is aimed at providing renewed hope to AD patients, addressing an unmet need for approved topical JAK inhibitors in India.

In March 2022, Pfizer Inc. furthered its market position through the acquisition of Arena Pharmaceuticals for $6.7 billion. This strategic move enhances Pfizer Inc.'s portfolio by adding potential drugs for gastroenterology, dermatology, and cardiology, including a potential follow-up to the inflammatory disorder drug Xeljanz (tofacitinib). Arena Pharmaceuticals, a US-based biopharmaceutical company, brings small-molecule medications into Pfizer Inc.'s pipeline, expanding the potential clinical applications across various therapeutic fields.

Major companies operating in the tofacitinib market include Beacon Pharmaceuticals Limited, Pfizer Inc., Globe Pharmaceuticals Ltd., Drug International Limited, Dolphin Pharmaceuticals, Lancer Therapeutics, Glenmark Pharmaceuticals LTD., Sun Pharmaceutical Industries Ltd., Shandong Octagon Chemicals Limited, Zydus Lifesciences Ltd., Esteve Pharmaceuticals SA, Unichem Laboratories, Beijing Mesochem Technology Co. Ltd, Aprazer Healthcare Pvt Ltd, Apino Pharma Co Ltd, Delta Pharma Limited, Mediconlife, Sandoz International GmbH, Mylan N.V., Hetero Drugs Limited, Torrent Pharmaceuticals Ltd., Lupin Limited, Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Ltd., Jubilant Life Sciences, Strides Pharma Science Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Limited.

North America was the largest region in the tofacitinib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tofacitinib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tofacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tofacitinib is a medication employed in the treatment of ulcerative colitis and various rheumatic diseases, including rheumatoid arthritis and ankylosing spondylitis. It is specifically used for moderate to severely active ulcerative colitis cases when there is intolerance, inadequate response, or a loss of response to biological therapy or conventional treatments.

The primary drug classes to which tofacitinib belongs include antirheumatic, Janus kinase inhibitor, and immunosuppressant. Antirheumatic denotes any medication utilized for treating rheumatism. Tofacitinib is available in strengths of 5mg, 10mg, 11mg, and 22mg, with administration routes including oral and others. The distribution channels for this medication encompass hospital pharmacies, retail pharmacies, and online pharmacies. Tofacitinib is indicated for conditions such as ulcerative colitis, rheumatoid arthritis, psoriasis, and others.

The tofacitinib market research report is one of a series of new reports that provides tofacitinib market statistics, including tofacitinib industry global market size, regional shares, competitors with tofacitinib market share, detailed tofacitinib market segments, market trends, and opportunities, and any further data you may need to thrive in the tofacitinib industry. This tofacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tofacitinib market consists of sales of Xeljanz and Xeljanz XR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.